acquired
Stage
About
Protomer Technologies develops glucose-responsive insulin receptor agonists using its proprietary Molecular Evolution of Peptide Sensors (MEPS) platform to create biotherapeutics that adjust activity based on blood sugar levels.
Explore Protomer Technologies's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.